Jump to ContentJump to Main Navigation
Show Summary Details

Journal of Medical Biochemistry

The Journal of Society of Medical Biochemists of Serbia


IMPACT FACTOR 2015: 0.742

SCImago Journal Rank (SJR) 2015: 0.204
Source Normalized Impact per Paper (SNIP) 2015: 0.333
Impact per Publication (IPP) 2015: 0.507

Open Access
Online
ISSN
1452-8266
See all formats and pricing

 


Select Volume and Issue
Loading journal volume and issue information...

Breast Cancer - Clinical Implication

Slađana Filipović1 / Aleksandra Filipović1 / Vladimir Stojiljković1 / Ivana Mišić1 / Vrbić Svetislav1 / Pejčić Ivica1 / Zorica Stanojević1

Clinical Centre of Niš, Clinic of Oncology, University of Niš, Niš1

This content is open access.

Citation Information: Journal of Medical Biochemistry. Volume 26, Issue 2, Pages 134–143, ISSN (Online) 1452-8266, ISSN (Print) 1452-8258, DOI: 10.2478/v10011-007-0017-5, April 2007

Publication History

Published Online:
2007-04-24

Karcinom Dojke - Kliničke Implikacije

Karcinom dojke (KD) je bolest kompleksne etiologije, prezentacije, karakteristika tumora i odgovora na terapiju. Starosna dob predstavlja najznačajniji faktor rizika, koji zajedno sa genetskom predispozicijom, trajanjem i prirodom reproduktivnog perioda žene (rana menarha-kasna menopauza, nuliparitet, kasna prva trudnoća, ne-dojenje), i delovanjem spoljašnjih faktora rizika (nutricija, fizička aktivnost, pušenje), čini KD najčešćim malignitetom u žena. Vodeći simptom jeste bezbolna, čvrsta, nepravilno ograničena masa u dojci. Dijagnoza se postavlja kombinacijom fizičkog pregleda, biopsije i neke od imidžing tehnika (mamografija, ultrazvuk, MR). Najznačajniji prognostički parametri su veličina tumora, nodalni status, histološki gradus, status hormonskih receptora. Hirurgija je i dalje osnova terapijskog pristupa, sa zračnom-, hemio-, hormono- ili ciljanom- terapijom, ili kombinacijom nekih od navedenih terapijskih modaliteta. I danas je petogodišnje preživljavanje od KD manje od 55%, što navodi na potrebu što hitnijeg uvođenja individualizovanog tretmana ove bolesti u klinič ku praksu.

Breast Cancer - Clinical Implication

Breast cancer (BC) is a disease underlined by a complex aetiology, natural history and disease behaviour. Age is the greatest risk factor, which coupled with genetic predisposition, hormonal phenotype, reproductive profile and extrinsic factors, make BC the commonest malignancy in women (23%). The most frequent presenting symptom of BC is a hard, painless, irregular lump. Profile of BC, respective of it's growth and invasiveness capacity is diverse. Principle prognostic indicators are nodal status, tumour size, histological grade and hormonal receptor status. Diagnosis is achieved by the combination of physical examination, FNAC or core biopsy and breast imaging (mammography/ultrasound). Surgery remains the mainstay of BC treatment, with or without radiation therapy, chemotherapy, hormonal manipulation, and state-of-the-art targeted treatment. Even in this day-and-age, less than 55% of BC sufferers have an overall survival longer than 5 years. This raises an alarm to bring the long awaited and much researched patient-tailored treatment to the clinic at the fastest possible pace.

Keywords: karcinom dojke; prognostički parametri; terapijski pristup

Keywords: Breast cancer; prognostic parameters; therapy approach

  • American Cancer Society. Cancer fact sand figures, 2001-2002. Atlanta, Georgia: American Cancer Society at: http://www.cancer.org

  • Advisory Committee on Cancer Prevention. Recomendation on cancer screening in the European Union. European Journal of Cancer 2000; 36: 1473-78.

  • Filipović S. Osnovi kliničke onkologije. Prosveta 1996; 21-27.

  • Sewell CW. Pathology of high risk breast leisions and ductal carcinoma in situ. Radiologic Clinics of North America 2004; 42: 821-30. [CrossRef]

  • Jacobs TW, Conolly JL, Schnitt SJ. Non malignant leisions in breast core needle biopsie: to excise or not excise? AM J Surg Pathol 2002; 26: 185-197.

  • Silva OE, Zurrida S. Breast Cancer: A Practical Guide. Elsevier 2000; 11-87.

  • Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas Thomas A, et al. Seqence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 1997; 16: 2417-25.

  • Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins MB. Efficancy of bilateral prophylactic mastectomy in women with a family history of brast cancer. 1999. N Engl J Med 1999; 340: 77-84. [CrossRef]

  • Perry N, Broeders M, Holand R. European guidelines for quality assurance in breast cancer screening and diagnosis. Forth Edition. 2006. European Commision.

  • Tabar L, Duffy SW, Vitak B, et al. The natural history of breast carcinoma: What have we learned from screening? Cancer 1999; 86: 449-62. [CrossRef] [PubMed]

  • Nicolini A, Carpi A, Tarro G. Biomolecular Markers of Breast Cancer. Frontiers in Bioscience 2006; 11: 1811-43.

  • Morris AD, Morris RD, Wilson JF, et al. Breast-conservingtherapy vs mastectomy in early-stage breast cancer: a meta-analysis of 10-year survival. Cancer J Sci Am 1997; 3: 6-12. [PubMed]

  • Šobić V, Vučković-Dekić Lj, Nešković-Konstantinović Z. Novine u dijagnostici i terapiji karcinoma dojke. 2005. Akademija medicinskih nauka SLD-a.

  • Stamatović Lj. Adjuvantna hemioterapija raka dojke. 2005. Maligni tumori dojke - UOHS.

  • Swenerton Kd et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1997; 39: 11-52.

  • Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. 2005. J Clin Oncol 2005; 23: 4265-74.

  • Burris HA. Docetaxel (Taxotere) in HER-2-positive patents and in combination with trastuzumab (Herceptin). Semin Oncol 2000; 27 (2 Suppl 3): 19.

Comments (0)

Please log in or register to comment.